Evaluation of a New Organization for Collecting Pre-chemotherapy Session Information

Inclusion Criteria: * The patient was informed about the implementation of the study, its objectives, constraints and patient rights * The patient has given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 6 months of follow-up * The patient is treated via anti-cancer chemotherapy for colorectal cancer * The patient is starting a new adjuvant or metastatic chemotherapy protocol with a follow-up in a day-clinic setting * The patient has already used a smartphone, or desires to learn how, or is accompanied by a person who can help the patient use a smartphone * The anticipated chemotherapy treatment corresponds to one of the following protocols: cetuximab, FOLFIRI, FOLFIRI-aflibercept, FOLFIRI-bevacizumab, FOLFIRI-cetuximab, FOLFIRI-panitumumab, Folfirinox, Folfirinox-bevacizumab, Folfoxiri, Folfoxiri-bevacizumab, FOLFOX 4 simplified, FOLFOX 4 simplified - bevacizumab, FOLFOX 4 simplified - cetuximab, FOLFOX 4 simplified - panitumumab, Irinotecan-cetuximab, LV5FU2 simplified, panitumumab, XELOX. Exclusion Criteria: * The patient is participating in another study, or has participated in another study within the past 3 months, that may influence the results or conclusions of the present trial * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, or is an adult under guardianship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * The planned chemotherapy regimen includes weekly treatment cycles * Patient who is incapable of using a smartphone either by himself/herself or via another helping person